source
- Mirum's hepatitis D antibody brelovitug meets primary endpoint in phase 3 trialMirum Pharmaceuticals announced that its experimental antiviral monoclonal antibody brelovitug achieved the primary efficacy goal in a phase 3 study for hepatitis D. The trial results continue a s…
- Mirum readies FDA filing after positive Phase 3 results for hepatitis D therapyMirum Pharmaceuticals announced that its hepatitis D candidate has met its primary goals in the second of two pivotal studies. The company said the data support moving the product toward regulatory…